Lipid and apolipoprotein ratios: Association with coronary artery disease and effects of rosuvastatin compared wtih atorvastatin, pravastatin, and simvastatin
Plasma lipid and apolipoprotein ratios that include both an atherogenic and an antiatherogenic lipid component (eg, total cholesterol/high-density lipoprotein [HDL] cholesterol ratio, low-density lipoprotein [LDL] cholesterol/HDL cholesterol ratio, non-HDL cholesterol/HDL cholesterol ratio, and apol...
Saved in:
Published in | The American journal of cardiology Vol. 91; no. 5A; p. C20 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
New York
Elsevier Limited
06.03.2003
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Plasma lipid and apolipoprotein ratios that include both an atherogenic and an antiatherogenic lipid component (eg, total cholesterol/high-density lipoprotein [HDL] cholesterol ratio, low-density lipoprotein [LDL] cholesterol/HDL cholesterol ratio, non-HDL cholesterol/HDL cholesterol ratio, and apolipoprotein [apo] B/apo A-I ratio) have been found to be strong predictors of coronary artery disease (CAD) risk. Three trials that compared the effects of rosuvastatin 10 mg versus atorvastatin 10 mg and 2 trials that compared the effects of rosuvastatin 10 mg versus simvastatin 20 mg and pravastatin 20 mg on lipid ratios in patients with hypercholesterolemia were prospectively designed for pooled analysis. At 12 weeks, in the 3-trial pooled analysis, rosuvastatin 10 mg (n = 389) showed significantly greater reductions in all 4 lipid ratios compared with atorvastatin 10 mg (n = 393) (p <0.001). The mean percent reduction from baseline in the LDL cholesterol/HDL cholesterol ratio was 51% in patients treated with rosuvastatin 10 mg versus 39% in patients treated with atorvastatin 10 mg. In the 2-trial pooled analysis, treatment with rosuvastatin 10 mg (n = 226) also resulted in significantly greater reductions in all 4 lipid ratios compared with both simvastatin 20 mg (n = 249) and pravastatin 20 mg (n = 252) (p <0.001). Mean percent reductions from baseline in the LDL cholesterol/HDL cholesterol ratio were 52%, 39%, and 30% for rosuvastatin 10 mg, simvastatin 20 mg, and pravastatin 20 mg, respectively, in these 2 trials. [PUBLICATION ABSTRACT] |
---|---|
AbstractList | Plasma lipid and apolipoprotein ratios that include both an atherogenic and an antiatherogenic lipid component (eg, total cholesterol/high-density lipoprotein [HDL] cholesterol ratio, low-density lipoprotein [LDL] cholesterol/HDL cholesterol ratio, non-HDL cholesterol/HDL cholesterol ratio, and apolipoprotein [apo] B/apo A-I ratio) have been found to be strong predictors of coronary artery disease (CAD) risk. Three trials that compared the effects of rosuvastatin 10 mg versus atorvastatin 10 mg and 2 trials that compared the effects of rosuvastatin 10 mg versus simvastatin 20 mg and pravastatin 20 mg on lipid ratios in patients with hypercholesterolemia were prospectively designed for pooled analysis. At 12 weeks, in the 3-trial pooled analysis, rosuvastatin 10 mg (n = 389) showed significantly greater reductions in all 4 lipid ratios compared with atorvastatin 10 mg (n = 393) (p <0.001). The mean percent reduction from baseline in the LDL cholesterol/HDL cholesterol ratio was 51% in patients treated with rosuvastatin 10 mg versus 39% in patients treated with atorvastatin 10 mg. In the 2-trial pooled analysis, treatment with rosuvastatin 10 mg (n = 226) also resulted in significantly greater reductions in all 4 lipid ratios compared with both simvastatin 20 mg (n = 249) and pravastatin 20 mg (n = 252) (p <0.001). Mean percent reductions from baseline in the LDL cholesterol/HDL cholesterol ratio were 52%, 39%, and 30% for rosuvastatin 10 mg, simvastatin 20 mg, and pravastatin 20 mg, respectively, in these 2 trials. [PUBLICATION ABSTRACT] |
Author | Davidson, Michael H Caplan, RIchard J Rader, Daniel J Pears, John S |
Author_xml | – sequence: 1 givenname: Daniel surname: Rader middlename: J fullname: Rader, Daniel J – sequence: 2 givenname: Michael surname: Davidson middlename: H fullname: Davidson, Michael H – sequence: 3 givenname: RIchard surname: Caplan middlename: J fullname: Caplan, RIchard J – sequence: 4 givenname: John surname: Pears middlename: S fullname: Pears, John S |
BookMark | eNqNjkFLA0EMhQep4Fb9D8GzCzu7ah1vIooHj72XsJulKe1kTGYt_hl_q1OxePUQHl9e3iNzN4sS6cRV_n4Rah98N3NV0zRtHfxNOHNzs01B72_vKvf1xokHwFgmyZaTJJVMHEExs9gDPJpJzweIsOe8hl5UIuonoGYqMrARGv100DhSnw1kBBWbPtByScaS2SVUGmCfeQ2YRY_WNSTFPziUGO-Oiwt3OuLW6PJXz93Vy_Py6bUuX75PZHm1kUljsVZt13SLtgmh-9fRN_2SYHA |
CODEN | AJCDAG |
ContentType | Journal Article |
Copyright | Copyright Elsevier Sequoia S.A. Mar 6, 2003 |
Copyright_xml | – notice: Copyright Elsevier Sequoia S.A. Mar 6, 2003 |
DBID | 7TS 8FD FR3 K9. M7Z NAPCQ P64 |
DatabaseName | Physical Education Index Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biochemistry Abstracts 1 Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts |
DatabaseTitle | Nursing & Allied Health Premium Technology Research Database Biochemistry Abstracts 1 ProQuest Health & Medical Complete (Alumni) Engineering Research Database Physical Education Index Biotechnology and BioEngineering Abstracts |
DatabaseTitleList | Nursing & Allied Health Premium |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-1913 |
ExternalDocumentID | 325253951 |
GroupedDBID | --- --K --M .55 .GJ .~1 0R~ 123 1B1 1RT 1~. 1~5 23M 3O- 4.4 457 4G. 53G 5RE 5VS 6J9 7-5 71M 7RV 7TS 8FD 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAQFI AAQQT AAWTL AAXKI AAXUO AAYOK ABBQC ABFNM ABLJU ABMAC ABOCM ABPPZ ABXDB ACDAQ ACGFO ACIUM ACIWK ACPRK ACRLP ADBBV ADEZE ADFRT ADMUD ADUKH AEKER AENEX AFCTW AFFNX AFKRA AFKWA AFRAH AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AHMBA AIEXJ AIKHN AITUG AJOXV AJRQY AKRWK ALIPV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR BENPR BKOJK BKOMP BLXMC BNPGV CS3 EBS EFJIC EJD EO9 EP2 EP3 EX3 F5P FDB FIRID FNPLU FR3 FYGXN G-Q HZ~ IH2 IHE J1W J5H K-O K9. KOM L7B M1P M29 M2O M41 M7Z MO0 N9A NAPCQ O-L O9- OAUVE OHT OZT P-9 P2P P64 PC. PQQKQ Q38 RIG ROL RPZ SDF SDG SEL SES SJN SPCBC SSH SSZ T5K TWZ UNMZH UV1 WH7 WOW X7M XPP YFH YOC YYP YZZ ZGI ~G- |
ID | FETCH-proquest_journals_2303720993 |
ISSN | 0002-9149 |
IngestDate | Fri Sep 13 09:39:59 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5A |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-proquest_journals_2303720993 |
PQID | 230372099 |
PQPubID | 41200 |
ParticipantIDs | proquest_journals_230372099 |
PublicationCentury | 2000 |
PublicationDate | 20030306 |
PublicationDateYYYYMMDD | 2003-03-06 |
PublicationDate_xml | – month: 03 year: 2003 text: 20030306 day: 06 |
PublicationDecade | 2000 |
PublicationPlace | New York |
PublicationPlace_xml | – name: New York |
PublicationTitle | The American journal of cardiology |
PublicationYear | 2003 |
Publisher | Elsevier Limited |
Publisher_xml | – name: Elsevier Limited |
SSID | ssj0001156 |
Score | 3.455831 |
Snippet | Plasma lipid and apolipoprotein ratios that include both an atherogenic and an antiatherogenic lipid component (eg, total cholesterol/high-density lipoprotein... |
SourceID | proquest |
SourceType | Aggregation Database |
StartPage | C20 |
SubjectTerms | Cardiovascular disease Drug therapy Lipids |
Title | Lipid and apolipoprotein ratios: Association with coronary artery disease and effects of rosuvastatin compared wtih atorvastatin, pravastatin, and simvastatin |
URI | https://www.proquest.com/docview/230372099/abstract/ |
Volume | 91 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LSsNAFB1qF-JGfKJWZRB3NiWP5lF3pbRU0QqSQnchL7GgSUlTQRd-it_ip3nn5UyoFHUTmhkypLmHO_feOWcGoXOTTLte6GpObKeQoHiG5oW2q8VJaEa2p4N7oCzfkTMct68n9qRW-1RYS4syasVvP-pK_mNVaAO7EpXsHyz7PSg0wG-wL1zBwnD9lY3JwdMJ226VHLYwy-muC0ShQr43Jbspn1_QzIucSnApmfNVrNDQURRyB0yei5eQyI0qRPVy-nhB0nTRRSw0K0L1llbip8-iSY1-fSljydQ9K2JKilXr-_dhwrDEJPBy8Ypy8OcVyr_UV_TC2RNf17qicjL5HLj-Yi64x7zeK4odFmV7ObICJ1Q4y-ov4tk7Btv-tJUyZ-65HQ3yUUv19uxsMI5qu6v47p6py0lREAFGd8FgfHMT-P2JX-1lMYBpm7bVIRr-NcsglNLWu6QYQbTtiPSLvNvSfE-DGH8LbfLsA3cZlLZRLc120Pot51fsog-KKAwmxFVEYYaoS6zgCRM8YYEnzPCEOZ7oGBxPOH_AKp6wwBMmeMIqnppYQVOTDqJgaQ-dDfp-b6iJ_xdwEM0DyHHJSUgQB--jepZn6QHCsRlDGGvokRGZ7dA1Iidy2rGnJxFML-A8DlFjxUBHK3sbaEMi5xjVy2KRnkDgWEan1DpfbP2DaA |
link.rule.ids | 315,786,790 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lipid+and+apolipoprotein+ratios%3A+Association+with+coronary+artery+disease+and+effects+of+rosuvastatin+compared+wtih+atorvastatin%2C+pravastatin%2C+and+simvastatin&rft.jtitle=The+American+journal+of+cardiology&rft.au=Rader%2C+Daniel+J&rft.au=Davidson%2C+Michael+H&rft.au=Caplan%2C+RIchard+J&rft.au=Pears%2C+John+S&rft.date=2003-03-06&rft.pub=Elsevier+Limited&rft.issn=0002-9149&rft.eissn=1879-1913&rft.volume=91&rft.issue=5A&rft.spage=C20&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=325253951 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-9149&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-9149&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-9149&client=summon |